Investing
Glaxosmithkline Ups Stake in Spero Therapeutics Inc (SPRO)
Published:
Last Updated:
Fintel reports that Glaxosmithkline Plc has filed a 13D/A form with the SEC disclosing ownership of 9,190,606 shares of Spero Therapeutics Inc (SPRO). This represents 19.99% of the company.
In their previous filing dated September 16, 2021 they reported 1,740,606 shares and 5.40% of the company, an increase in shares of 428.01% and an increase in total ownership of 14.59% (calculated as current – previous percent ownership).
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
What are other large shareholders doing?
Aquilo Capital Management, LLC holds 5,321,231 shares representing 12.52% ownership of the company. In it’s prior filing, the firm reported owning 5,281,504 shares, representing an increase of 0.75%. The firm decreased its portfolio allocation in SPRO by 80.07% over the last quarter.
Bvf Inc/il holds 3,089,615 shares representing 7.27% ownership of the company. In it’s prior filing, the firm reported owning 1,585,615 shares, representing an increase of 48.68%. The firm decreased its portfolio allocation in SPRO by 79.97% over the last quarter.
Atlas Venture Associates IX, LLC holds 1,376,968 shares representing 3.24% ownership of the company. No change in the last quarter.
Atlas Venture Life Science Advisors, LLC holds 1,031,160 shares representing 2.43% ownership of the company. No change in the last quarter.
Renaissance Technologies Llc holds 939,017 shares representing 2.21% ownership of the company. In it’s prior filing, the firm reported owning 109,100 shares, representing an increase of 88.38%. The firm decreased its portfolio allocation in SPRO by 26.01% over the last quarter.
What is the overall institutional sentiment?
There are 188 funds or institutions reporting positions in Spero Therapeutics Inc. This is a decrease of 34 owner(s) or 15.32%.
Average portfolio weight of all funds dedicated to Spero Therapeutics Inc is 0.0581%, a decrease of 5.9867%. Total shares owned by institutions decreased in the last three months by 0.80% to 20,401,134 shares.
Based on this information, institutional sentiment is bearish.
This article originally appeared on Fintel
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
